CO5251434A1 - Composicion de liberacion controlada - Google Patents

Composicion de liberacion controlada

Info

Publication number
CO5251434A1
CO5251434A1 CO00097407A CO00097407A CO5251434A1 CO 5251434 A1 CO5251434 A1 CO 5251434A1 CO 00097407 A CO00097407 A CO 00097407A CO 00097407 A CO00097407 A CO 00097407A CO 5251434 A1 CO5251434 A1 CO 5251434A1
Authority
CO
Colombia
Prior art keywords
composition
release layer
pharmaceutically active
active agent
sustained
Prior art date
Application number
CO00097407A
Other languages
English (en)
Inventor
Y Lin Shun
L Wearley Lorraine
Dilip J Gole
Gary W Posage
Paul K Wilkinson
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of CO5251434A1 publication Critical patent/CO5251434A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La presente invención se relaciona con una composición que comprende una capa de liberación sostenida y una capa de liberación rápida; la capa de liberación sostenida comprende un polímero hidrosoluble y un primer agente farmacéuticamente activo; la capa de liberación rápida comprende un agente formador de matriz y un segundo agente farmacéuticamente activo; generalmente, la composición provee liberación rápida y sostenida (o controlada) de un agente farmacéuticamente activo por lo menos durante 6 horas y de preferencia por lo menos de 1 a 3 días; la composición se puede incorporar en forma unitaria de dosificación, tal como un inserto vaginal; también se proveen métodos para preparar la composición.
CO00097407A 1999-12-23 2000-12-22 Composicion de liberacion controlada CO5251434A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47182599A 1999-12-23 1999-12-23

Publications (1)

Publication Number Publication Date
CO5251434A1 true CO5251434A1 (es) 2003-02-28

Family

ID=23873133

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00097407A CO5251434A1 (es) 1999-12-23 2000-12-22 Composicion de liberacion controlada

Country Status (14)

Country Link
US (1) US20050074490A1 (es)
EP (1) EP1110541B1 (es)
JP (1) JP2001278779A (es)
KR (1) KR20010057581A (es)
CN (1) CN1302604A (es)
AR (1) AR027907A1 (es)
AU (1) AU7251100A (es)
BR (1) BR0007360A (es)
CA (1) CA2329574A1 (es)
CO (1) CO5251434A1 (es)
DE (1) DE60015059T2 (es)
ES (1) ES2228418T3 (es)
HK (1) HK1037144A1 (es)
MX (1) MXPA01000121A (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2366794A (en) * 2000-09-13 2002-03-20 Procter & Gamble Process for making a foam component
KR20030006788A (ko) * 2001-07-16 2003-01-23 이승진 치주질환 치료용 서방출성 고분자제제
US20060039974A1 (en) * 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7037522B2 (en) * 2002-09-27 2006-05-02 Western Holdings, L.L.C. Nocturnal muscle enhancing composition and method
BRPI0414500A (pt) 2003-09-19 2006-11-07 Drugtech Corp formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
ES2308065T3 (es) * 2004-04-30 2008-12-01 Topotarget Germany Ag Formulacion que comprende un inhibidor de histona desacetilasa, que exhibe una liberacion bifasica.
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EP1830886B1 (en) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
ITFI20050215A1 (it) * 2005-10-13 2007-04-14 Valpharma Internat S P A Composizione nutrizionale a base di amminoacidi
CA2635994A1 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Drug delivery system for bioadhesion to a vulvovaginal surface
US20070281008A1 (en) * 2006-06-05 2007-12-06 Lin Shun Y Personal lubricant compositions and kits for providing personal lubrication
WO2008081590A1 (ja) * 2006-12-27 2008-07-10 Fujifilm Corporation 医療用組成物
US10548839B2 (en) * 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
US9545376B2 (en) 2013-01-23 2017-01-17 Arx, Llc Production of unit dose constructs
EP3089854B1 (en) 2013-12-31 2018-11-21 Johnson & Johnson Consumer Inc. Single-pass process for forming a multilayered shaped film product, product and apparatus
RU2700870C2 (ru) * 2013-12-31 2019-09-23 Джонсон энд Джонсон Консьюмер Инк. Способ формования пленочного продукта
WO2015103030A1 (en) * 2013-12-31 2015-07-09 Johnson & Johnson Consumer Companies, Inc. Process for forming a multi layered shaped film
US11026883B2 (en) * 2016-10-13 2021-06-08 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
WO2018078548A1 (en) * 2016-10-25 2018-05-03 Catalent U.K. Swindon Zydis Limited Compositions of different densities for fast disintegrating multi-layer tablet

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234091A (en) * 1955-07-08 1966-02-08 Ciba Geigy Corp Shaped medicaments and process for their manufacture
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
DE3212412C2 (de) * 1982-04-02 1986-01-02 Dr. Ruhland Nachf. GmbH, 8425 Neustadt Gewebeverklebbare kollagene Wundauflage
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US4915953A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering acetaminophen or phenylpropanolamine
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5558880A (en) * 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
IT1251114B (it) * 1991-07-26 1995-05-04 Farcon Ag Forme farmaceutiche antivirali per applicazione vaginale
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
CA2105887C (en) * 1992-09-10 2004-03-16 Peter Britton Bioerodible device for administering active ingredients
US5354558A (en) * 1992-09-10 1994-10-11 Mcneil-Pcc, Inc. Bioerodible contraceptive suppository
US5631023A (en) * 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5738875A (en) * 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5656283A (en) * 1995-06-08 1997-08-12 Ortho Pharmaceutical Corporation In-situ lyophilization of vaginal suppository in unit dose applicator and resultant product
CN1158071C (zh) * 1997-05-30 2004-07-21 渗透有限公司 多层渗透装置
PT1003476E (pt) * 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives

Also Published As

Publication number Publication date
MXPA01000121A (es) 2002-10-23
AU7251100A (en) 2001-06-28
EP1110541B1 (en) 2004-10-20
BR0007360A (pt) 2001-08-14
DE60015059T2 (de) 2005-12-15
US20050074490A1 (en) 2005-04-07
AR027907A1 (es) 2003-04-16
CN1302604A (zh) 2001-07-11
DE60015059D1 (de) 2004-11-25
EP1110541A1 (en) 2001-06-27
KR20010057581A (ko) 2001-07-04
HK1037144A1 (en) 2003-04-24
CA2329574A1 (en) 2001-06-23
ES2228418T3 (es) 2005-04-16
JP2001278779A (ja) 2001-10-10

Similar Documents

Publication Publication Date Title
CO5251434A1 (es) Composicion de liberacion controlada
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
BRPI0406172B8 (pt) dispositivo de entrega de agente ativo minimamente invasiva de biomaterial
AR044547A1 (es) Sistema de distribucion de drogas
GB9908014D0 (en) Pharmaceutical compositions
CO5210891A1 (es) Formulaciones agroquimicas
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
NZ591802A (en) Oral and personal care compositions and methods
ES2175799T3 (es) Forma de dosificacion para administracion en aerosol.
AR032352A1 (es) Composicion farmaceutica bioadhesiva de hidratacion gradual y su uso en la fabricacion de un medicamento para la administracion de testosterona y terbutalina a un mamifero a traves de una superficie de mucosa.
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
BR9917089A (pt) Composições e métodos para distribuição mucosal
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
AR044131A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
GB2415142A (en) Porous matrix
CO5271728A1 (es) Forma de dosificacion de farmaco en capas impulsadas por hidrogel
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
PE44799A1 (es) Antagonistas del receptor de vitronectina
AR086688A2 (es) Composicion farmaceutica con excipiente liquido modificado, un metodo para producir una composicion farmaceutica y el uso de dicha composicion para preparar un medicamento
HK1040920A1 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent.
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
DK1171101T3 (da) Fremgangsmåde til fremstilling af en vanduoplöselig amorf depotmatrix
AR035064A1 (es) 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos
MXPA01013460A (es) Formulaciones topicas que comprenden agentes de penetracion de la piel y uso de las mismas.

Legal Events

Date Code Title Description
FC Application refused